CVS Health stock weighs stronger Q3 results and a higher outlook

CVS Health reported stronger third-quarter results on November 4, 2026, and raised its full-year targets. The healthcare company said revenue, adjusted earnings and cash generation benefited from improved performance across its operating segments, while it kept a cautious view on medical costs and broader economic risks.

For the three months ended September 30, CVS Health generated revenue of 108.4 billion US dollars, up 5.4 percent from 102.9 billion US dollars a year earlier. Adjusted earnings per share rose to 2.09 US dollars from 1.60 US dollars. Diluted GAAP earnings were 1.68 US dollars per share, compared with a loss of 3.13 US dollars in the prior-year quarter.

The year-over-year GAAP comparison benefited from the absence of a 5.7 billion US dollar goodwill impairment charge recorded in the third quarter of 2025. CVS Health also reported adjusted operating income of 4.194 billion US dollars, compared with 3.459 billion US dollars a year earlier. The company said the improvement reflected gains across all operating segments.

Benefits Segment Shows Recovery

The Health Care Benefits segment was the main contributor to the improvement. Its revenue increased 2.4 percent to 36.855 billion US dollars, while adjusted operating income climbed to 912 million US dollars from 314 million US dollars. The medical benefit ratio declined to 91.3 percent from 92.8 percent, a development that points to better underlying performance in the Government business.

Health Services revenue advanced 9.5 percent to 53.964 billion US dollars, and adjusted operating income edged up to 2.106 billion US dollars from 2.050 billion US dollars. Pharmacy and Consumer Wellness revenue fell 2.0 percent to 35.498 billion US dollars, but adjusted operating income increased 10.6 percent to 1.635 billion US dollars. CVS Health attributed the revenue pressure in part to regulatory-related price reductions, generic drug launches and pharmacy reimbursement pressure.

Higher Targets Meet Cost Caution

CVS Health raised its full-year 2026 adjusted earnings-per-share target to at least 8.20 US dollars from a previous range of 7.90 to 8.10 US dollars. The company also lifted its GAAP diluted earnings target to at least 6.98 US dollars from a range of 6.84 to 7.04 US dollars.

Management increased its cash-flow-from-operations target to at least 15.5 billion US dollars from at least 11.5 billion US dollars. The company said the revisions reflected stronger expectations for Health Care Benefits and Pharmacy and Consumer Wellness, but highlighted continued elevated cost trends and potential macroeconomic headwinds.

CVS Health stock traded at 81.29 euros on Lang & Schwarz at 13:19 CET on Thursday, November 12, 2026. The quote places the focus on how investors assess the combination of improved operating performance, higher cash-flow expectations and continuing pressure on healthcare costs.

CVS Health's broader US market backdrop remains relevant as investors weigh company-specific execution against macroeconomic risks.

Further attention will center on medical-cost trends, segment profitability and the company's ability to convert its stronger nine-month operating cash flow into sustainable full-year performance. More news and analyses on CVS Health stock will follow developments.

Source: CVS Health investor relations.